It was a mixed day for Acorda Therapeutics Inc., which said Fampridine-SR missed its endpoints in two pivotal Phase III trials in spinal cord injury (SCI), but also said the drug showed positive trends in a Phase II multiple sclerosis (MS) trial. (BioWorld Today)
With first-quarter results that significantly surpassed analyst expectations, investors might find themselves shaking their heads or smiling widely - depending on whether or not they bought Genentech Inc.'s stock a year ago when it was running in the mid-$30 range. (BioWorld Today)
As Indevus Pharmaceuticals Inc.'s overactive bladder product nears the market, the company laid out a U.S. commercialization plan with Zagreb, Croatia-based Pliva d.d. (BioWorld Today)
Pricing significantly below its intended range, Memory Pharmaceuticals Corp. raised $35 million in its initial public offering Monday. (BioWorld Today)
